Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Mortier, Virginie ^a   Dauwe, Kenny ^a   Vancoillie, Leen ^a   Staelens, Delfien ^a   Van Wanzeele, Filip ^b   Vogelaers, Dirk ^b   Vandekerckhove, Linos ^b   Chalmet, Kristen ^a   Verhofstede, Chris ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; VIRUS DNA; VIRUS RNA; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CXCR4 PROTEIN, HUMAN; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CORECEPTOR SWITCH; DNA SEQUENCE; FEMALE; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NONHUMAN; PHYLOGENY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; VIRAL TROPISM; VIRUS MUTATION; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM;

ANTI-RETROVIRAL AGENTS; CCR5 RECEPTOR ANTAGONISTS; CYCLOHEXANES; GENOTYPE; HIV-1; HUMANS; PHYLOGENY; RECEPTORS, CCR5; RECEPTORS, CXCR4; TRIAZOLES;

EID: 84892413027     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080259     Document Type: Article

References (44)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services. Available: http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Section accessed May 07, 2013
2. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B et al. (2011) European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 11: 394-407. doi:10.1016/S1473-3099(10)70319-4. PubMed: 21429803.
3. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700. doi:10.1146/annurev.immunol.17.1.657. PubMed: 10358771.
4. Regoes RR, Bonhoeffer S (2005) The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 13: 269-277. doi:10.1016/j.tim.2005.04. 005. PubMed: 15936659.
5. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M et al. (1997) Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 127: 882-890. doi:10.7326/0003-4819-127-10-199711150- 00004. PubMed: 9382366.
6. Fenyö EM, Albert J, Asjö B (1989) Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 3 (Suppl 1): S5-12. doi:10.1097/00002030-198901001-00002. PubMed: 2514754.
7. Mild M, Kvist A, Esbjörnsson J, Karlsson I, Fenyö EM et al. (2010) Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol 10: 356-364. doi:10.1016/j.meegid.2009.05.003. PubMed: 19446658.
8. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE et al. (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66: 1354-1360. PubMed: 1738194.
9. Richman DD, Bozzette SA (1994) The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 169: 968-974. doi:10.1093/infdis/169.5.968. PubMed: 7909549.
10. Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD (1993) A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 168: 1374-1379. doi:10.1093/infdis/ 168.6.1374. PubMed: 7902382.
11. Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M et al. (2007) Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 45: 643-649. doi:10.1086/520650. PubMed: 17683002.
12. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C et al. (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 44: 591-595. doi:10.1086/511035. PubMed: 17243065.
13. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT et al. (1993) Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118: 681-688. doi:10.7326/0003-4819-118-9- 199305010-00004. PubMed: 8096374.
14. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S et al. (1999) Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 179: 254-258. doi:10.1086/314539. PubMed: 9841850.
15. Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L et al. (2007) HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. AIDS 21: 2243-2245. doi:10.1097/QAD.0b013e3282f0e3d0. PubMed: 18090053.
16. Waters LJ, Scourfield AT, Marcano M, Gazzard BG, Bower M et al. (2011) The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. Clin Infect Dis 52: 671-673. doi:10.1093/cid/ciq198. PubMed: 21292672.
17. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI et al. (2008) Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359: 1442-1455. doi:10.1056/NEJMoa0803154. PubMed: 18832245.
18. Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K et al. (2011) Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. HIV Med 12: 544-552. doi:10.1111/j.1468-1293.2011. 00922.x. PubMed: 21518222.
19. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK et al. (2007) Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 12: 1097-1106. PubMed: 18018768.
20. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK et al. (2011) Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 203: 237-245. doi:10.1093/infdis/jiq030. PubMed: 21288824.
21. Poveda E, Alcamí J, Paredes R, Córdoba J, Gutiérrez F et al. (2010) Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Res 12: 135-148. PubMed: 20842202.
22. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M et al. (2009) Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75: 7537-7541. doi:10.1128/AEM.01541-09. PubMed: 19801464.
23. Hall TA: BioEdit (1999); a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series 41: 95-98
24. Posada D, Crandall KA (1998) MODELTEST: testing the model of DNA substitution. Bioinformatics 14: 817-818. doi:10.1093/bioinformatics/14.9.817. PubMed: 9918953.
25. Swofford DL (2003) PAUP*. Phylogenetic analysis using parsimony (*and other methods). Sunderland, MA: Sinauer Associates.
26. Letunic I, Bork P (2007) Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics 23: 127-128. doi:10.1093/bioinformatics/btl529. PubMed: 17050570.
27. Letunic I, Bork P (2011) Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. Nucleic Acids Res 39: W475-W478. doi:10.1093/nar/gkr201. PubMed: 21470960.
28. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW et al. (2006) Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 194: 926-930. doi:10.1086/507312. PubMed: 16960780.
29. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR (1997) Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 185: 621-628. doi:10.1084/jem.185.4.621. PubMed: 9034141.
30. Shepherd JC, Jacobson LP, Qiao W, Jamieson BD, Phair JP et al. (2008) Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 198: 1104-1112. doi:10.1086/591623. PubMed: 18783316.
31. Margolis L, Shattock R (2006) Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 4: 312-317. doi:10.1038/nrmicro1387. PubMed: 16541138.
32. Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G et al. (2009) Co-receptor switch during HAART is independent of virological success. J Med Virol 81: 2036-2044. doi:10.1002/jmv.21598. PubMed: 19856465.
33. Svicher V, Cento V, Rozera G, Abbate I, Santoro MM et al. (2013) The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing. PLOS ONE 8: e53603. doi:10.1371/journal.pone.0053603. PubMed: 23341955.
34. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388. doi:10.1128/JVI.77.24.13376-13388.2003. PubMed: 14645592.
35. Pastore C, Ramos A, Mosier DE (2004) Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 78: 7565-7574. doi:10.1128/JVI.78.14.7565-7574.2004. PubMed: 15220431.
36. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66: 6777-6780. PubMed: 1404617.
37. Dybowski JN, Heider D, Hoffmann D (2010) Structure of HIV-1 quasi-species as early indicator for switches of co-receptor tropism. AIDS Res Ther 7: 41. doi:10.1186/1742-6405-7-41. PubMed: 21118549.
38. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG et al. (1992) Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66: 3183-3187. PubMed: 1560543.
39. Cicala C, Arthos J, Fauci AS (2010) HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med 9 (Suppl. 1): S2. doi:10.1186/1479-5876-9-S1-S2. PubMed: 21284901.
40. Schuitemaker H, van 't Wout AB, Lusso P (2011) Clinical significance of HIV-1 coreceptor usage. J Transl Med 9 (Suppl 1): S5. doi:10.1186/1479-5876-9- S2-I5. PubMed: 21284904.
41. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C et al. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-725. doi:10.1038/382722a0. PubMed: 8751444.
42. McGovern RA, Thielen A, Mo T, Dong W, Woods CK et al. (2010) Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24: 2517-2525. doi:10.1097/QAD.0b013e32833e6cfb. PubMed: 20736814.
43. Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F et al. (2010) Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 7: 56. doi:10.1186/1742-4690-7-56. PubMed: 20591141.
44. Mulinge M, Lemaire M, Servais JY, Rybicki A, Struck D et al. (2013) HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRRF01-AE and CRF02-AG. PLOS ONE 8: e60566. doi:10.1371/journal.pone.0060566. PubMed: 23667426.